A novel eye drop platform and its use to treat Namd


  •  Global neovascular AMD market, estimated at $6.9 billion in 2018, is projected to reach $10.4 billion by 2024, registering a CAGR of 7.1% during the forecast period.
  • Eye drop provides alternative self-care treatment for AMD patients compared to intravitreal(IVT) injection of VEGF antibodies by ophthalmologists.


  • Proprietary combination of FDA approved excipients
  • Increase drug solubility
  • Show excellent ocular penetration
  • No ocular irritation


 Booth No. L1010